Clinical Trial Update: FXS6837 for the Treatment of IgAN Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of FXS6837 for IgA nephropathy is listed as not yet recruiting, with Shanghai Fosun Pharmaceutical as sponsor.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• FXS6837

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: IgAN | Phase 2 | Status: NOT_YET_RECRUITING